Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia
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Therapeutic options to treat chronic lymphocytic leukemia (B-CLL) are at present unsatisfactory. In the present work, we provide the rationale for using clofazimine, which exhibits a very good safety profile and is already used to cure leprosy. Clofazimine might represent a novel treatment for B-CLL, which is characterized by a clonal accumulation of mature neoplastic B cells that are resistant to apoptosis. Ion channels are involved in different aspects of tumor progression due to their ability to regulate proliferation, apoptosis and migration. The expression of the shaker-type Kv1.3 potassium channel differs in various cancer tissues 1 and the quantity of Kv1.3 mRNA was found to be slightly higher in B-CLL cells than in B cells from healthy people. 2 Kv1.3, which is crucial for proliferation, 3 may confer a survival advantage on proliferating cancer cells.
We and others have previously shown that Kv1.3 is expressed both in the plasma membrane (PM) and in the inner mitochondrial membrane. 4 Furthermore, in several cell lines, the expression of Kv1.3 in the PM correlates with its expression in the mitochondria. 5, 6 We have also previously identified mitochondrial Kv1.3 (mtKv1.3) as a target of Bax and demonstrated physical interaction between the two proteins in apoptotic cells. 7, 8 Incubating Kv1.3-positive-isolated mitochondria with Bax triggered apoptotic events including mitochondrial membrane depolarization, reactive oxygen species (ROS) production and cytochrome c release, whereas Kv1.3-deficient mitochondria were resistant. Psora-4, PAP-1 and clofazimine, three distinct membrane-permeant inhibitors of Kv1.3, induced death by directly targeting the mitochondrial channel in multiple human and mouse cancer cell lines. 5 Importantly, these drugs activated the intrinsic apoptotic pathway also in the absence of Bax and Bak. Genetic deficiency or siRNA-mediated downregulation of Kv1.3 abrogated the effects of the drugs, providing specificity of their action via Kv1.3. Clofazimine reduced tumor size by 90% in an orthotopic melanoma mouse model in vivo. 5 Here, we first addressed whether B cells from B-CLL patients show higher Kv1.3 protein expression and activity than B cells from healthy subjects. Healthy B cells (defined as single-positive CD19 cells) or pathologic B cells (defined as double-positive CD19/ CD5 cells) 9 were purified from peripheral blood lymphocytes. The level of Kv1.3 protein in the two types of cells was determined by fluorescence-activated cell sorting using a FITC-labeled anti-Kv1.3 antibody (specificity was confirmed by studies of CTLL-2 lymphocytes that either expressed or lacked the channel (Supplementary Figures S1A and B) ). B-CLLs expressing Kv1.3 were positive for CD5 (Supplementary Figure S1C) . Cells from B-CLL patients expressed higher levels of Kv1.3 than B cells from healthy subjects (Figure 1a) , although the levels varied in individual patients. Patch clamp experiments in the whole-cell configuration confirmed higher expression of functional Kv1.3: the peak current measured at þ 70 mV was significantly higher in the B-CLL than in control B cells (Figure 1b ). Kv1.3 was blocked by ShK (30 nM), a membrane-impermeant specific inhibitor, and clofazimine (2 mM) (not shown). Subcellular fractionation experiments revealed that B-CLL cells express Kv1.3 also in their mitochondria (Figure 1c) in agreement with the previously observed correlation between Kv1.3 expression levels in the PM and mitochondria. This correlation was further confirmed in primary CCR7
À T cells that express significantly more Kv1.3 in their PM, 3 and also in their mitochondria (Supplementary Figure  S1D) than do CCR7 þ cells. Given the presence of mtKv1.3 in B-CLL cells, we tested whether membrane-permeant Kv1.3 inhibitors induce apoptosis in B-CLL cells. Psora-4, PAP-1 and clofazimine, membrane-permeant inhibitors of Kv1.3, very efficiently induced death of B-CLL cells, in particular if administered in combination with inhibitors of the multidrug resistance pumps, so that export from the cells can be avoided ( Figure 1d ) (n ¼ 29 patients). In contrast, the cells were resistant to the membrane-impermeant inhibitor ShK, clearly indicating that the PM-located Kv1.3 itself is not responsible for the apoptotic response. Clofazimine, an inhibitor of both Kv1.3 and multidrug resistance, 10 was also effective alone at a concentration of 10 mM (Figure 1d) . B or T cells isolated from healthy subjects were resistant to these stimuli (Figures 1e and f and Supplementary Figure S2A ). Most importantly, when we separated residual T lymphocytes from neoplastic B cells taken from a B-CLL patient, 11 treatment induced apoptosis only in the pathologic B cells, sparing the residual normal T cells (Figure 1g ). Moreover, human peripheral blood monocytes were resistant to Psora-4, PAP-1 and clofazimine (Supplementary Figures S2B and C). Finally, injection of clofazimine into mice at a dose that has been previously shown to effectively eliminate a melanoma in vivo 5 did not result in any significant change of blood cell counts (Supplementary Table I ).
In general, pathologic B cells showed higher channel expression and were sensitive to treatment, whereas healthy cells, which expressed less Kv1.3 protein, were resistant to the drugs. However, T lymphocytes from two B-CLL patients expressed relatively high levels of Kv1.3 but were resistant to treatment (Supplementary Figure S3) , a finding clearly suggesting that specificity of the drugs towards pathologic cells is not merely due to higher expression of Kv1.3 in all cases. A chronic increase in the mitochondrial ROS (mtROS) levels has been proposed to be involved both in initiating and promoting cancer development. 12 We observed an increased mtROS production and a marked depolarization in B-CLL cells after treatment with the drugs (Supplementary Figure S4) in agreement with the previously described mechanism of action of these inhibitors. 5 These effects cannot be observed either in B-CLL cells treated with the impermeant inhibitor ShK or in healthy B cells (Supplementary Figure S4 ). Thus, we tested whether a mild mitochondrial oxidative stress may render healthy cells that express Kv1.3 sensitive to permeant channel inhibitors. We preincubated healthy B cells with a sublethal dose of 7-O-(4-triphenylphosphoniumbutyl) quercetin iodide (Q-7BTPI), a quercetin derivative targeted to mitochondria and shown to act as a pro-oxidant. 13 This pre-incubation indeed stimulated mtROS production as measured by MitoSOX assay (Figure 2a ), but alone did not induce apoptosis (Figure 2b) . The subsequent addition of Kv1.3 inhibitors (except ShK) induced a rapid and significant increase in mtROS and subsequent apoptosis (Figure 2a Conversely, pre-treatment of pathologic B cells with membranepermeant catalase and superoxide dismutase (PEG-CAT and PEG-SOD) abolished the apoptosis-inducing effect of Kv1.3 inhibitors (Figures 2c and d) . The same results were obtained also with residual T cells and pathologic B cells of the same patient (Supplementary Figure S3) . Application of the same oxidative stress plus Kv1.3 inhibitors did not induce apoptosis in murine CTLL-2 lymphocytes that lack Kv1.3 ( Figure 2e ), a finding further indicating a synergistic action of Kv1.3 and ROS.
We hypothesized that as the drugs act on mtKv1.3, which comes into play at a relatively late stage in the intrinsic apoptotic process, death might be induced independently of the expression of PM-associated known prognostic factors. Supplementary Table II shows the total number of white blood cells, percentage of lymphocytes, results of cytogenetic analysis by fluorescence in situ hybridization and the progression of the disease (according to the Rai staging system) in 29 patients. Supplementary Figure S5A illustrates that apoptosis occurs upon treatment of the cells, independently both from the expression of ZAP70 or CD38 and of somatic hypermutation or mutation of p53. In addition, data shown in Supplementary Figure S5B reveal an increase in the expression of antiapoptotic Bcl-2 in most of the B-CLL samples isolated from patients, as expected.
DISCUSSION
Our study demonstrates that mtKv1.3 inhibitors are potent and selective inducers of B-CLL apoptosis via the intrinsic pathway. Importantly, they kill B-CLL cells while sparing the residual T cells even of the same patient, and act on B-CLL cells independently of current prognostic factors. We show that a synergistic action of Kv1.3 expression level and of altered redox state in the malignant B-CLL cells accounts for the selective action of our drugs. Indeed, B-CLL cells express functional Kv1.3 at higher levels than control B cells.
Owing to their particular metabolism, cancer cells are characterized by an altered redox homeostasis and by a more evident oxidative stress as compared to normal cells. 12 Our findings strongly suggest that B-CLL cells are no exception and that their selective elimination occurs when oxidative stress exceeds a critical threshold. Lower concentrations of ROS, or their efficient elimination in non-pathologic cells, protect these cells from the effects of Kv1.3 blockers. Cancer cells exhibit an increased susceptibility to oxidative stress-induced cell death with respect to normal cells, 14 suggesting that a causal link exists between increased steady-state levels of mtROS production and sensitivity to death. Therapies that are able to specifically increase mtROS production in cancer cells are expected to selectively trigger apoptosis in these cells, as observed with mitochondrially targeted anticancer drugs (mitocans). 12, 13 Our study demonstrates that mtKv1.3 inhibitors work independently of the currently available prognostic factors in this disorder. 15 Furthermore, B-CLL cells are characterized by a higher level of expression of the antiapoptotic Bcl-2 proteins. As the drugs used in this study 'bypass' the action of Bax, which is a critical apoptotic factor believed to be neutralized by Bcl-2, they can also induce apoptosis in the case of Bcl-2 overexpression. Importantly, one of these inhibitors, clofazimine, is already used as antimicrobial agent in daily clinical practice against leprosis and other diseases. Clofazimine, which is well tolerated at doses up to 100 mg once daily, 16 may be a promising new therapeutic tool for the treatment of B-CLL patients.
